Lancet RM:硫酸镁对急性重症哮喘患儿有效(MAGNETIC研究)

2013-08-15 青楚 医学论坛网

几乎没有证据表明雾化吸入型硫酸镁(MgSO4)在儿童急性哮喘中的作用,英国学者的一项研究评估了儿童急性重症哮喘使用硫酸镁治疗的效果。结果显示,总体来说,作为标准治疗的辅助治疗,雾化吸入型等渗硫酸镁在急性重症哮喘患儿的平均ASS评分中没有展示出显著的临床改善。但是,在严重发作(血氧饱和度小于92%)和进行性症状持续小于6小时的患儿中可观察到最大的临床反应。相关研究发表于《柳叶刀》杂志(the Lan

几乎没有证据表明雾化吸入型硫酸镁(MgSO4)在儿童急性哮喘中的作用,英国学者的一项研究评估了儿童急性重症哮喘使用硫酸镁治疗的效果。结果显示,总体来说,作为标准治疗的辅助治疗,雾化吸入型等渗硫酸镁在急性重症哮喘患儿的平均ASS评分中没有展示出显著的临床改善。但是,在严重发作(血氧饱和度小于92%)和进行性症状持续小于6小时的患儿中可观察到最大的临床反应。相关研究发表于《柳叶刀》杂志(the Lancet)。

该随机安慰剂对照的多中心平行试验于2009年1月3日~2011年3月20日期间,纳入来自于英国30家医院未接受标准吸入治疗的急性重症哮喘的儿童(2~16岁)508名。在雾化吸入沙丁胺醇和异丙托溴铵的基础上,患儿被随机分配(1:1)为同时使用22.5 mL的等渗硫酸镁(250 mmol/L;151 mg/剂量;硫酸镁组,N=252),或者同时使用2.5 mL的等渗盐水(安慰剂组,N=256),每20分钟给药一次,共给药3次。随机分配通过计算机生成的随机序列完成,该序列为2~4个的随机模块大小。分配方案对所有患者和研究者保密。主要结局测量为随机后60分钟的Yung哮喘严重程度评分(ASS)。我们应用统计学显著意义的P<0.05的水平作为组间差异,将 ASS中组间差异0.5作为最小临床显著性治疗效果。采用意向治疗分析。

结果显示,60分钟时的平均ASS评分在硫酸镁组中(4.72 [SD 1.37])低于安慰剂组(4.95 [SD 1.40]; 校正差−0.25,95% 置信区间[CI], −0.48~−0.02; P=0.03)。该差异无临床显著性意义。临床效果在更严重的哮喘恶化(P=0.03)和症状存在小于6小时(P=0.049)的儿童更显著。各组间的不良事件的发生率没有差异。

原文链接:

Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial.  The Lancet Respiratory Medicine, 2013,1(4):301 - 308

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=294856, encodeId=d623294856b2, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 11:02:32 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38390, encodeId=be63383901f, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:12:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733647, encodeId=14b11e3364798, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jun 11 11:09:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827610, encodeId=96d7182e6100d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 16 05:09:00 CST 2014, time=2014-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445722, encodeId=80e61445e221d, content=<a href='/topic/show?id=6634e3575cf' target=_blank style='color:#2F92EE;'>#硫酸镁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73575, encryptionId=6634e3575cf, topicName=硫酸镁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0f15173844, createdName=xxxx1051, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581631, encodeId=292f1581631c7, content=<a href='/topic/show?id=b0779593446' target=_blank style='color:#2F92EE;'>#重症哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95934, encryptionId=b0779593446, topicName=重症哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a33316846488, createdName=siiner, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2018-03-10 owlhealth

    不错耶.学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=294856, encodeId=d623294856b2, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 11:02:32 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38390, encodeId=be63383901f, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:12:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733647, encodeId=14b11e3364798, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jun 11 11:09:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827610, encodeId=96d7182e6100d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 16 05:09:00 CST 2014, time=2014-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445722, encodeId=80e61445e221d, content=<a href='/topic/show?id=6634e3575cf' target=_blank style='color:#2F92EE;'>#硫酸镁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73575, encryptionId=6634e3575cf, topicName=硫酸镁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0f15173844, createdName=xxxx1051, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581631, encodeId=292f1581631c7, content=<a href='/topic/show?id=b0779593446' target=_blank style='color:#2F92EE;'>#重症哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95934, encryptionId=b0779593446, topicName=重症哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a33316846488, createdName=siiner, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2015-10-11 hlycom3356

    感谢作者分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=294856, encodeId=d623294856b2, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 11:02:32 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38390, encodeId=be63383901f, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:12:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733647, encodeId=14b11e3364798, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jun 11 11:09:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827610, encodeId=96d7182e6100d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 16 05:09:00 CST 2014, time=2014-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445722, encodeId=80e61445e221d, content=<a href='/topic/show?id=6634e3575cf' target=_blank style='color:#2F92EE;'>#硫酸镁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73575, encryptionId=6634e3575cf, topicName=硫酸镁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0f15173844, createdName=xxxx1051, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581631, encodeId=292f1581631c7, content=<a href='/topic/show?id=b0779593446' target=_blank style='color:#2F92EE;'>#重症哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95934, encryptionId=b0779593446, topicName=重症哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a33316846488, createdName=siiner, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2014-06-11 canlab
  4. [GetPortalCommentsPageByObjectIdResponse(id=294856, encodeId=d623294856b2, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 11:02:32 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38390, encodeId=be63383901f, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:12:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733647, encodeId=14b11e3364798, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jun 11 11:09:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827610, encodeId=96d7182e6100d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 16 05:09:00 CST 2014, time=2014-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445722, encodeId=80e61445e221d, content=<a href='/topic/show?id=6634e3575cf' target=_blank style='color:#2F92EE;'>#硫酸镁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73575, encryptionId=6634e3575cf, topicName=硫酸镁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0f15173844, createdName=xxxx1051, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581631, encodeId=292f1581631c7, content=<a href='/topic/show?id=b0779593446' target=_blank style='color:#2F92EE;'>#重症哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95934, encryptionId=b0779593446, topicName=重症哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a33316846488, createdName=siiner, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2014-02-16 howi
  5. [GetPortalCommentsPageByObjectIdResponse(id=294856, encodeId=d623294856b2, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 11:02:32 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38390, encodeId=be63383901f, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:12:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733647, encodeId=14b11e3364798, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jun 11 11:09:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827610, encodeId=96d7182e6100d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 16 05:09:00 CST 2014, time=2014-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445722, encodeId=80e61445e221d, content=<a href='/topic/show?id=6634e3575cf' target=_blank style='color:#2F92EE;'>#硫酸镁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73575, encryptionId=6634e3575cf, topicName=硫酸镁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0f15173844, createdName=xxxx1051, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581631, encodeId=292f1581631c7, content=<a href='/topic/show?id=b0779593446' target=_blank style='color:#2F92EE;'>#重症哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95934, encryptionId=b0779593446, topicName=重症哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a33316846488, createdName=siiner, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=294856, encodeId=d623294856b2, content=不错耶.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 10 11:02:32 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38390, encodeId=be63383901f, content=感谢作者分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 11 21:12:00 CST 2015, time=2015-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733647, encodeId=14b11e3364798, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jun 11 11:09:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827610, encodeId=96d7182e6100d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Feb 16 05:09:00 CST 2014, time=2014-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445722, encodeId=80e61445e221d, content=<a href='/topic/show?id=6634e3575cf' target=_blank style='color:#2F92EE;'>#硫酸镁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73575, encryptionId=6634e3575cf, topicName=硫酸镁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0f15173844, createdName=xxxx1051, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581631, encodeId=292f1581631c7, content=<a href='/topic/show?id=b0779593446' target=_blank style='color:#2F92EE;'>#重症哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95934, encryptionId=b0779593446, topicName=重症哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a33316846488, createdName=siiner, createdTime=Sat Aug 17 09:09:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]

相关资讯

FDA修改硫酸镁注射液药品标签

  美国食品与药物管理局(FDA)基于“若妊娠女性使用硫酸镁注射液超过5~7天,可能导致发育中胎儿出现低血钙和骨骼问题(包括骨质疏松和骨折)”这一新安全信息,修改硫酸镁注射液药品标签。   硫酸镁注射液被用于预防先兆子痫妊娠女性出现癫痫发作,并治疗子痫妊娠女性的癫痫发作。使用该药物治疗早产是标签外用药。   硫酸镁注射液药品标签新增加内容包括:   ⑴ 妊娠期连续应用该药物治疗早产

FDA警告:慎用硫酸镁阻止早产

  2013年5月30日,美国食品药品管理局(FDA)发布了一则警告,反对硫酸镁注射剂用于阻止孕妇早产的用药时间>5~7天,以免导致胎儿风险。胎儿可能出现低钙水平、骨质减少以及骨折,可导致损害的最短治疗时间尚不清楚。   硫酸镁已被批准用于预防先兆子痫患者癫痫以及控制子痫患者癫痫发作,而用于阻止早产则属于超适应证使用。   FDA已通过其不良事件报告系统确认了18例有关宫内硫酸镁暴露新生儿骨骼

FDA限制使用硫酸镁用于预防早产

5月30日,美国食品药品管理局(FDA)建议临床医生,在预防早产时不要对孕妇连续使用硫酸镁超过5至7天,因为这种药物可能会对正在发育的胎儿骨骼有损害。FDA解释说,硫酸镁只被批准用于预防子痫前期的癫痫发作,其用于安胎的超出适应症范围的标签外使用能导致婴儿低钙水平、骨量减少或者骨折。 针对这种药物影响的警示内容已被列入药物标签中,其致畸类别也正由A类改为D类。同时药品标签也被修订,强调注射用硫酸镁